Through social listening analysis of three years of hereditary angioedema (HAE) patient and caregiver conversations, this report captures the authentic voice across the diagnostic journey, treatment landscape, and support ecosystem, revealing where the system is failing and where meaningful intervention can make a measurable difference in quality of life.
Treatment for ATTR-CM and ATTR-PN took a significant step forward with the approval of the first targeted therapies in 2018/2019. With label and access expansions underway, and new MoAs on the horizon, top-level physician-stated and patient-level insights from Ipsos’ ATTR Therapy Monitor provide visibility of the evolving landscapes of these two conditions.
The haemophilia treatment landscape has evolved significantly in recent years, with novel approaches such as bispecific antibodies and gene therapy advancing treatment options. Top-level insights from Ipsos’ Haemophilia Therapy Monitor highlight key physician-stated and real-world patient metrics to consider when planning for launch of a new asset or defending an existing asset in this market.